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disease management program. As such, future efforts should be
developed to increase retention in disease management programs
designed for Medicaid recipients.
PDB29
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OBJECTIVE: To evaluate the effect of insulin treatment on
health care utilization among type-II diabetics. More aggressive
glucose control treatment, particularly with insulin, is known to
slow diabetic patients’ disease progression. Does it also reduce
health care utilization and cost in the short run? METHODS:
Medical, pharmacy, and laboratory claims for 369 type-II dia-
betes patients enrolled in a single managed care plan were eval-
uated. Patients were continuously eligible for at least two years
between June, 2001 and June, 2004. Separate variables were
computed for each year. The propensity score (PS) calculated
with classiﬁcation and regression trees (C&RT) was used to cal-
culate the probability of receiving insulin treatment, using year
one health status, demographics, and HgA1c laboratory values.
These probabilities were then used as weights in the regression
of total health care costs and ambulatory costs in year two on
an array of variables including insulin use. RESULTS: Insulin
treatment does not beneﬁt all groups of patients equally. Patients
over the age of 60 beneﬁt signiﬁcantly from insulin treatment
with a reduction in total health care cost of 60.5% (p = 0.0007)
and a reduction in ambulatory cost of 60.9% (p = 0.0008) com-
pared to younger diabetic patients (age < 60). CONCLUSION:
Diabetic patients age 60 or above and the health care payers
would greatly beneﬁt from better glucose control through insulin
treatment.
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OBJECTIVES: Diabetes is a progressive disease that often
requires periodic intensiﬁcation of treatment to control hyper-
glycemia. The objective of this study is to evaluate therapy
changes after initiation of metformin and sulfonylurea combi-
nation therapy. METHODS: This was a retrospective analysis of
data derived from the IMS Mediplus UK primary care database.
Patients were selected using the following criteria: type-2 dia-
betes diagnosis, age ≥30 years at diagnosis, initiation of OHA
combination with MF and SU between January 1, 1997 and
March 31, 2003. Patients with prior insulin prescription were
excluded. RESULTS: A toal of 6616 patients were included, with
a mean age of 62.82 years (±12.12) and 56.3% of male; 2603
patients (39.39%) had a history of macrovascular events and
647 (9.79%) had microvascular events. Hypertension (78.39%)
and dyslipidemia (59.89%) were also common among these
patients. The average follow-up was about 36.7 months. After
three years of initiating metformin and sulfonylurea combination
therapy, 54.8% had changed their therapy, either by discontin-
uing one or both initial agents, adding a third oral agent or
receiving insulin. No patient remained on the initial combination
after 6.5 years. Approximately 8–11% of patients changed
therapy every six-months during the ﬁrst ﬁve-years. By the end
of two years, about 14.1% have required insulin therapy and
10% had switched to another OHA combination therapy.
Approximately 46.9% of patients were prescribed insulin
therapy after seven-years. CONCLUSION: In this cohort of 
diabetic patients managed by GPs in the UK, a large number 
of patients require additional oral anti-hyperglycemic agents or
insulin to manage their hyperglycemia. More effective therapies
are needed in order to better manage these patients.
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OBJECTIVE: To investigate factors associated with health care
cost saving in patients with diabetes to the California Medicaid
Populations (Medi-Cal). METHODS: A retrospective study was
conducted by using claims data from January, 1995 to Decem-
ber, 2000. Dependent variable was total health care cost. His-
torical data including demographic factors, health care cost and
utilization, diabetes drug treatment, follow-up services based on
diabetic guidelines, medication compliance, complications, and
comorbidities were used as independent variables. The general-
ized estimating equation method was used to analyze the panel
data. RESULTS: Various factors have a signiﬁcant association
with health care cost savings to MediCal. Patients taking both
insulin and oral hypoglycemic drugs or patients having drug dose
increased had health care costs higher by $1210 and $141,
respectively. Patients having oral hypoglycemic or insulin, anti-
hypertensive, or lipid lowering drugs added also had health care
costs higher by $264, $528, or $199, respectively. In addition,
patients having drugs changed to different classes or to insulin
had health care costs higher by $1018. However, patients having
one percent of medication compliance increased had health care
costs lower by $7 in next six-month period. Moreover, patients
having ofﬁce visits based on diabetic guidelines or patients
having glucose monitoring strip had health care costs lower by
$730 or $258 in next six-month period, respectively. In addition,
patients having lab tests [e.g., HbA1C test every six-months
($121), cholesterol check up every year ($472), or dilated eye
check-up every year ($260)] could lower costs in the future.
CONCLUSIONS: Medi-Cal policy makers may implement some
disease management programs or health policy on patients who
have drug treatment problems and patients without follow-up
services based on diabetic guidelines in order to improve patient
outcomes and decrease health care costs in the future.
PDB32
THE RELATIONSHIP BETWEEN PATIENT’S TYPE OF PAYMENT
AND PRESCRIPTION DRUG COSTS FOR DIABETIC PATIENTS
Ngorsuraches S1, Sisang T2
1Prince of Songkla University, Hatyai, Songkla,Thailand; 2Maharaj
Nakorn Sri Thammarat Hospital, Muang, Nakorn Sri Thamm,Thailand
OBJECTIVE: To examine the relationship between patient’s
payment type and prescription drug costs for diabetic outpatients
at a regional hospital in southern Thailand. METHODS:
Patient’s proﬁle and prescription for 1454 outpatients who used
anti-diabetic drugs between August and September 2002 were
collected. The patient’s type of payment was divided into two
groups, which were patients who paid out-of-pocket and patients
who did not pay for their prescriptions. Descriptive and linear
regression analyses were used to examine the relationship.
RESULTS: Results showed that average drug costs per prescrip-
tion between patients who paid out-of-pocket and patients who
